PPARA and osteoarthritis: Physiological findings of inflammatory experimental models of osteoarthritis demonstrated that 30 mg/day pioglitazone, a PPAR α > γ agonist [10, 42], ameliorated most aspects of joint lesions of the femoral condyles rather than those of the tibial plateaus [22, 44].